Device Trial Radar · NCT04818502
Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
May 4, 2021
Primary completion
Apr 4, 2024
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Mar 26, 2021
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and performance of the Tendyne™ Mitral Valve System when used as intended in a contemporary, real-world setting.
Conditions
- Mitral Valve Regurgitation
Interventions
Tendyne™ Mitral Valve SystemDevice
Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Endpoint for MR Elimination at 1 YearTime frame: At 1 year
Locations
36 sites in 13 countries. Site status is shown where the registry gives one.
Kepler University Hospital
Linz, Austria
UZ Gasthuisberg
Leuven, Belgium
University Hospital Olomouc
Olomouc, Czechia
33 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.